BACKGROUND: EMR is commonly performed before radiofrequency ablation (RFA) for nodular dysplastic Barrett's esophagus (BE). OBJECTIVE: To determine the efficacy and safety of EMR before RFA for nodular BE with advanced neoplasia (high-grade dysplasia [HGD] or intramucosal carcinoma [IMC]). DESIGN: Retrospective study. SETTING: University of North Carolina Hospitals, from 2006 to 2011. PATIENTS: 169 patients with BE with advanced neoplasia: 65 patients treated with EMR and RFA for nodular disease and 104 patients treated with RFA alone for nonnodular disease. INTERVENTIONS: EMR, RFA. MAIN OUTCOME MEASUREMENTS: Efficacy (complete eradication of dysplasia, complete eradication of intestinal metaplasia, total treatment sessions, RFA treatment sessions), safety (stricture formation, bleeding, and hospitalization). RESULTS: EMR followed by RFA achieved complete eradication of dysplasia and complete eradication of intestinal metaplasia in 94.0% and 88.0% of patients, respectively, compared with 82.7% and 77.6% of patients, respectively, in the RFA-only group (P = .06 and P = .13, respectively). The complication rates between the 2 groups were similar (7.7% vs 9.6%, P = .79). Strictures occurred in 4.6% of patients in the EMR-before-RFA group. compared with 7.7% of patients in the RFA-only group (P = .53). LIMITATIONS: Retrospective study at a tertiary-care referral center. CONCLUSION: In patients treated with EMR before RFA for nodular BE with HGD or IMC, no differences in efficacy and safety outcomes were observed compared with RFA alone for nonnodular BE with HGD or IMC. EMR followed by RFA is safe and effective for patients with nodular BE and advanced neoplasia.
BACKGROUND: EMR is commonly performed before radiofrequency ablation (RFA) for nodular dysplastic Barrett's esophagus (BE). OBJECTIVE: To determine the efficacy and safety of EMR before RFA for nodular BE with advanced neoplasia (high-grade dysplasia [HGD] or intramucosal carcinoma [IMC]). DESIGN: Retrospective study. SETTING: University of North Carolina Hospitals, from 2006 to 2011. PATIENTS: 169 patients with BE with advanced neoplasia: 65 patients treated with EMR and RFA for nodular disease and 104 patients treated with RFA alone for nonnodular disease. INTERVENTIONS: EMR, RFA. MAIN OUTCOME MEASUREMENTS: Efficacy (complete eradication of dysplasia, complete eradication of intestinal metaplasia, total treatment sessions, RFA treatment sessions), safety (stricture formation, bleeding, and hospitalization). RESULTS: EMR followed by RFA achieved complete eradication of dysplasia and complete eradication of intestinal metaplasia in 94.0% and 88.0% of patients, respectively, compared with 82.7% and 77.6% of patients, respectively, in the RFA-only group (P = .06 and P = .13, respectively). The complication rates between the 2 groups were similar (7.7% vs 9.6%, P = .79). Strictures occurred in 4.6% of patients in the EMR-before-RFA group. compared with 7.7% of patients in the RFA-only group (P = .53). LIMITATIONS: Retrospective study at a tertiary-care referral center. CONCLUSION: In patients treated with EMR before RFA for nodular BE with HGD or IMC, no differences in efficacy and safety outcomes were observed compared with RFA alone for nonnodular BE with HGD or IMC. EMR followed by RFA is safe and effective for patients with nodular BE and advanced neoplasia.
Authors: Ngozi I Okoro; Yutaka Tomizawa; Kelly T Dunagan; Lori S Lutzke; Kenneth K Wang; Ganapathy A Prasad Journal: Clin Gastroenterol Hepatol Date: 2011-11-02 Impact factor: 11.382
Authors: Lorenza Alvarez Herrero; Frederike G I van Vilsteren; Roos E Pouw; Fiebo J W ten Kate; Mike Visser; Cornelis A Seldenrijk; Mark I van Berge Henegouwen; Paul Fockens; Bas L A M Weusten; Jaques J G H M Bergman Journal: Gastrointest Endosc Date: 2011-02-02 Impact factor: 9.427
Authors: Frederik Hvid-Jensen; Lars Pedersen; Asbjørn Mohr Drewes; Henrik Toft Sørensen; Peter Funch-Jensen Journal: N Engl J Med Date: 2011-10-13 Impact factor: 91.245
Authors: Virender K Sharma; H Jae Kim; Ananya Das; Christopher D Wells; Cuong C Nguyen; David E Fleischer Journal: Am J Gastroenterol Date: 2009-01-27 Impact factor: 10.864
Authors: J J Gondrie; R E Pouw; C M T Sondermeijer; F P Peters; W L Curvers; W D Rosmolen; K K Krishnadath; F Ten Kate; P Fockens; J J Bergman Journal: Endoscopy Date: 2008-05 Impact factor: 10.093
Authors: Nicholas J Shaheen; Prateek Sharma; Bergein F Overholt; Herbert C Wolfsen; Richard E Sampliner; Kenneth K Wang; Joseph A Galanko; Mary P Bronner; John R Goldblum; Ana E Bennett; Blair A Jobe; Glenn M Eisen; M Brian Fennerty; John G Hunter; David E Fleischer; Virender K Sharma; Robert H Hawes; Brenda J Hoffman; Richard I Rothstein; Stuart R Gordon; Hiroshi Mashimo; Kenneth J Chang; V Raman Muthusamy; Steven A Edmundowicz; Stuart J Spechler; Ali A Siddiqui; Rhonda F Souza; Anthony Infantolino; Gary W Falk; Michael B Kimmey; Ryan D Madanick; Amitabh Chak; Charles J Lightdale Journal: N Engl J Med Date: 2009-05-28 Impact factor: 91.245
Authors: Adam C Strauss; Agoston T Agoston; Parambir S Dulai; Amitabh Srivastava; Richard I Rothstein Journal: Surg Endosc Date: 2014-12 Impact factor: 4.584
Authors: Cary C Cotton; W Asher Wolf; Sarina Pasricha; Nan Li; Ryan D Madanick; Melissa B Spacek; Kathleen Ferrell; Evan S Dellon; Nicholas J Shaheen Journal: Gastrointest Endosc Date: 2015-03-24 Impact factor: 9.427
Authors: N Li; S Pasricha; W J Bulsiewicz; R E Pruitt; S Komanduri; H C Wolfsen; G W Chmielewski; F S Corbett; K J Chang; N J Shaheen Journal: Dis Esophagus Date: 2015-06-30 Impact factor: 3.429
Authors: Sarina Pasricha; Cary Cotton; Kelly E Hathorn; Nan Li; William J Bulsiewicz; W Asher Wolf; V Raman Muthusamy; Srinadh Komanduri; Herbert C Wolfsen; Ron E Pruitt; Atilla Ertan; Gary W Chmielewski; Nicholas J Shaheen Journal: Gastroenterology Date: 2015-06-25 Impact factor: 22.682
Authors: Georgina Chadwick; Jack Faulkner; Robert Ley-Greaves; Panagiotis Vlavianos; Rob Goldin; Jonathan Hoare Journal: World J Gastrointest Endosc Date: 2015-01-16